Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Small, Large Molecules), By Workflow, By Therapeutics Area, By Service Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Drug Discovery Outsourcing Market Growth & Trends
The global drug discovery outsourcing market size is expected t%li%reach USD 10.23 billion by 2030 and is expected t%li%expand at a CAGR of 7.58% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc., The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies t%li%opt for outsourcing their research activities t%li%academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.
This scenari%li%is expected t%li%sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies t%li%develop medicines that extend life expectancy. According t%li%the United Nations, people aged 65 years between 2015 and 2020 are expected t%li%live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers t%li%expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.
The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine t%li%combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain t%li%combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry t%li%center stage with drug discovery outsourcing becoming a key aspect t%li%develop effective treatments against the virus. This is expected t%li%boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.
Drug Discovery Outsourcing Market Report Highlights
Drug Discovery Outsourcing Market Growth & Trends
The global drug discovery outsourcing market size is expected t%li%reach USD 10.23 billion by 2030 and is expected t%li%expand at a CAGR of 7.58% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc., The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies t%li%opt for outsourcing their research activities t%li%academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.
This scenari%li%is expected t%li%sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies t%li%develop medicines that extend life expectancy. According t%li%the United Nations, people aged 65 years between 2015 and 2020 are expected t%li%live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers t%li%expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.
The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine t%li%combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain t%li%combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry t%li%center stage with drug discovery outsourcing becoming a key aspect t%li%develop effective treatments against the virus. This is expected t%li%boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.
Drug Discovery Outsourcing Market Report Highlights
- On the basis of workflow segment, the market is segmented int%li%target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow.
- On the basis of therapeutics area segment, the market is segmented int%li%Respiratory System, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective, Central Nervous System, Dermatology, and Genitourinary System.
- On the basis of drug type segment, the market is segmented int%li%Small Molecules, and Large Molecules (Biopharmaceuticals).
- On the basis of service type segment, the market is segmented int%li%Chemistry Services, and Biology Services. The chemistry segment dominated the market with the largest revenue share in 2024, owing t%li%increasing number of outsourcing projects for small molecules across the industry.
- On the basis of end use segment, the market is segmented int%li%Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. The pharmaceutical & biotechnology companies segment dominated the market with the largest revenue share in 2024.
- Asia Pacific market held the largest market share of 45.99% in 2024. This growth can be attributed t%li%various factors, such as rising healthcare expenditure and growing demand for pharmaceutical products.
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Workflow
1.2.2. Therapeutics Area
1.2.3. Drug type
1.2.4. Service Type
1.2.5. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. DRUG DISCOVERY OUTSOURCING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing R&D In Biopharmaceutical Industry
3.2.1.2. Increasing demand for outsourcing Services in Drug Development
3.2.1.3. Increasing number of partnerships in drug discovery research
3.2.1.4. Technological advancements in drug discovery
3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of open-source software packages for drug discovery
3.2.2.2. High manufacturing costs coupled with high risk of drug failure
3.3. Drug Discovery Outsourcing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. DRUG DISCOVERY OUTSOURCING MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030
4.4. Target Identification & Screening
4.4.1. Target Identification & Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Target Validation & Functional Informatics
4.5.1. Target Validation & Functional Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Lead Identification & Candidate Optimization
4.6.1. Lead Identification & Candidate Optimization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Preclinical Development
4.7.1. Preclinical Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Other Associate Workflow
4.8.1. Other Associate Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. DRUG DISCOVERY OUTSOURCING MARKET: THERAPEUTICS AREA ESTIMATES & TREND ANALYSIS
5.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
5.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics, 2018 - 2030
5.4. Respiratory System
5.4.1. Respiratory System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Pain and Anesthesia
5.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Oncology
5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Ophthalmology
5.7.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Hematology
5.8.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Cardiovascular
5.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Endocrine
5.10.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.11. Gastrointestinal
5.11.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.12. Immunomodulation
5.12.1. Immunomodulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.13. Anti-Infective
5.13.1. Anti-Infective Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.14. Central Nervous System
5.14.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.15. Dermatology
5.15.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.16. Genitourinary System
5.16.1. Genitourinary System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. DRUG DISCOVERY OUTSOURCING MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Drug Discovery Outsourcing Market, By Drug Type: Segment Dashboard
6.2. Drug Discovery Outsourcing Market, By Drug Type: Movement Analysis
6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
6.4. Small Molecules
6.4.1. Small Molecules Market, 2018 to 2030, (USD Million)
6.5. Large Molecules (Biopharmaceuticals)
6.5.1. Large Molecules (Biopharmaceuticals) Market, 2018 to 2030, (USD Million)
CHAPTER 7. DRUG DISCOVERY OUTSOURCING MARKET: SERVICE TYPE ESTIMATES & TREND ANALYSIS
7.1. Drug Discovery Outsourcing Market, By Service Type: Segment Dashboard
7.2. Drug Discovery Outsourcing Market, By Service Type: Movement Analysis
7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service Type, 2018 - 2030
7.4. Chemistry Services
7.4.1. Chemistry Services Market, 2018 to 2030, (USD Million)
7.5. Biology Services
7.5.1. Biology Services Market, 2018 to 2030, (USD Million)
CHAPTER 8. DRUG DISCOVERY OUTSOURCING MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
8.4. Pharmaceutical & Biotechnology companies
8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 to 2030, (USD Million)
8.5. Academic Institutes
8.5.1. Academic Institutes Market, 2018 to 2030, (USD Million)
CHAPTER 9. DRUG DISCOVERY OUTSOURCING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. North America
9.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.2. U.S
9.4.2.1. Key Country Dynamics
9.4.2.2. Competitive Scenario
9.4.2.3. Regulatory Framework
9.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3. Canada
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4. Mexico
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Europe
9.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.2. UK
9.5.2.1. Key Country Dynamics
9.5.2.2. Competitive Scenario
9.5.2.3. Regulatory Framework
9.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3. Germany
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.4. Italy
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.5. France
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.6. Spain
9.5.6.1. Key Country Dynamics
9.5.6.2. Competitive Scenario
9.5.6.3. Regulatory Framework
9.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.7. Netherland
9.5.7.1. Key Country Dynamics
9.5.7.2. Competitive Scenario
9.5.7.3. Regulatory Framework
9.5.7.4. Netherland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.8. Belgium
9.5.8.1. Key Country Dynamics
9.5.8.2. Competitive Scenario
9.5.8.3. Regulatory Framework
9.5.8.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.9. Switzerland
9.5.9.1. Key Country Dynamics
9.5.9.2. Competitive Scenario
9.5.9.3. Regulatory Framework
9.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.10. Russia
9.5.10.1. Key Country Dynamics
9.5.10.2. Competitive Scenario
9.5.10.3. Regulatory Framework
9.5.10.4. Russia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.11. Sweden
9.5.11.1. Key Country Dynamics
9.5.11.2. Competitive Scenario
9.5.11.3. Regulatory Framework
9.5.11.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Asia Pacific
9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. China
9.6.2.1. Key Country Dynamics
9.6.2.2. Competitive Scenario
9.6.2.3. Regulatory Framework
9.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.3. Japan
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.4. Australia
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Framework
9.6.4.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.5. South Korea
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Regulatory Framework
9.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.6. India
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. Regulatory Framework
9.6.6.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.7. Thailand
9.6.7.1. Key Country Dynamics
9.6.7.2. Competitive Scenario
9.6.7.3. Regulatory Framework
9.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.8. Malaysia
9.6.8.1. Key Country Dynamics
9.6.8.2. Competitive Scenario
9.6.8.3. Regulatory Framework
9.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.9. Indonesia
9.6.9.1. Key Country Dynamics
9.6.9.2. Competitive Scenario
9.6.9.3. Regulatory Framework
9.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.10. Singapore
9.6.10.1. Key Country Dynamics
9.6.10.2. Competitive Scenario
9.6.10.3. Regulatory Framework
9.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.11. Philippines
9.6.11.1. Key Country Dynamics
9.6.11.2. Competitive Scenario
9.6.11.3. Regulatory Framework
9.6.11.4. Philippines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Latin America
9.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.2. Brazil
9.7.2.1. Key Country Dynamics
9.7.2.2. Competitive Scenario
9.7.2.3. Regulatory Framework
9.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Competitive Scenario
9.7.3.3. Regulatory Framework
9.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.4. Colombia
9.7.4.1. Key Country Dynamics
9.7.4.2. Competitive Scenario
9.7.4.3. Regulatory Framework
9.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.5. Chile
9.7.5.1. Key Country Dynamics
9.7.5.2. Competitive Scenario
9.7.5.3. Regulatory Framework
9.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8. MEA
9.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.2. South Africa
9.8.2.1. Key Country Dynamics
9.8.2.2. Competitive Scenario
9.8.2.3. Regulatory Framework
9.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.3. Saudi Arabia
9.8.3.1. Key Country Dynamics
9.8.3.2. Competitive Scenario
9.8.3.3. Regulatory Framework
9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.4. UAE
9.8.4.1. Key Country Dynamics
9.8.4.2. Competitive Scenario
9.8.4.3. Regulatory Framework
9.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.5. Kuwait
9.8.5.1. Key Country Dynamics
9.8.5.2. Competitive Scenario
9.8.5.3. Regulatory Framework
9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.6. Israel
9.8.6.1. Key Country Dynamics
9.8.6.2. Competitive Scenario
9.8.6.3. Regulatory Framework
9.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.7. Egypt
9.8.7.1. Key Country Dynamics
9.8.7.2. Competitive Scenario
9.8.7.3. Regulatory Framework
9.8.7.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Market Participant Categorization
10.2. Company Market Share Analysis, 2024
10.3. Company Profiles
10.3.1. Albany Molecular Research Inc.
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. EVOTEC
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Laboratory Corporation of America Holdings
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. GenScript
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Pharmaceutical Product Development, LLC
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Charles River Laboratories
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. WuXi AppTec
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Merck & Co., Inc.
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Thermo Fisher Scientific Inc
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Dalton Pharma Services
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Oncodesign
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Jubilant Biosys
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. DiscoverX Corp.
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. QIAGEN
10.3.14.1. Company Overview
10.3.14.2. Financial Performance
10.3.14.3. Service Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Eurofins SE
10.3.15.1. Company Overview
10.3.15.2. Financial Performance
10.3.15.3. Service Benchmarking
10.3.15.4. Strategic Initiatives
10.3.16. Syngene International Limited
10.3.16.1. Company Overview
10.3.16.2. Financial Performance
10.3.16.3. Service Benchmarking
10.3.16.4. Strategic Initiatives
10.3.17. Dr. Reddy Laboratories Ltd.
10.3.17.1. Company Overview
10.3.17.2. Financial Performance
10.3.17.3. Service Benchmarking
10.3.17.4. Strategic Initiatives
10.3.18. Pharmaron Beijing Co., Ltd.
10.3.18.1. Company Overview
10.3.18.2. Financial Performance
10.3.18.3. Service Benchmarking
10.3.18.4. Strategic Initiatives
10.3.19. TCG Lifesciences Pvt Ltd.
10.3.19.1. Company Overview
10.3.19.2. Financial Performance
10.3.19.3. Service Benchmarking
10.3.19.4. Strategic Initiatives
10.3.20. Domainex Ltd.
10.3.20.1. Company Overview
10.3.20.2. Financial Performance
10.3.20.3. Service Benchmarking
10.3.20.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Workflow
1.2.2. Therapeutics Area
1.2.3. Drug type
1.2.4. Service Type
1.2.5. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. DRUG DISCOVERY OUTSOURCING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing R&D In Biopharmaceutical Industry
3.2.1.2. Increasing demand for outsourcing Services in Drug Development
3.2.1.3. Increasing number of partnerships in drug discovery research
3.2.1.4. Technological advancements in drug discovery
3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of open-source software packages for drug discovery
3.2.2.2. High manufacturing costs coupled with high risk of drug failure
3.3. Drug Discovery Outsourcing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. DRUG DISCOVERY OUTSOURCING MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030
4.4. Target Identification & Screening
4.4.1. Target Identification & Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Target Validation & Functional Informatics
4.5.1. Target Validation & Functional Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Lead Identification & Candidate Optimization
4.6.1. Lead Identification & Candidate Optimization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Preclinical Development
4.7.1. Preclinical Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Other Associate Workflow
4.8.1. Other Associate Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. DRUG DISCOVERY OUTSOURCING MARKET: THERAPEUTICS AREA ESTIMATES & TREND ANALYSIS
5.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
5.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics, 2018 - 2030
5.4. Respiratory System
5.4.1. Respiratory System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Pain and Anesthesia
5.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Oncology
5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Ophthalmology
5.7.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Hematology
5.8.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Cardiovascular
5.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Endocrine
5.10.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.11. Gastrointestinal
5.11.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.12. Immunomodulation
5.12.1. Immunomodulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.13. Anti-Infective
5.13.1. Anti-Infective Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.14. Central Nervous System
5.14.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.15. Dermatology
5.15.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.16. Genitourinary System
5.16.1. Genitourinary System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. DRUG DISCOVERY OUTSOURCING MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Drug Discovery Outsourcing Market, By Drug Type: Segment Dashboard
6.2. Drug Discovery Outsourcing Market, By Drug Type: Movement Analysis
6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
6.4. Small Molecules
6.4.1. Small Molecules Market, 2018 to 2030, (USD Million)
6.5. Large Molecules (Biopharmaceuticals)
6.5.1. Large Molecules (Biopharmaceuticals) Market, 2018 to 2030, (USD Million)
CHAPTER 7. DRUG DISCOVERY OUTSOURCING MARKET: SERVICE TYPE ESTIMATES & TREND ANALYSIS
7.1. Drug Discovery Outsourcing Market, By Service Type: Segment Dashboard
7.2. Drug Discovery Outsourcing Market, By Service Type: Movement Analysis
7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service Type, 2018 - 2030
7.4. Chemistry Services
7.4.1. Chemistry Services Market, 2018 to 2030, (USD Million)
7.5. Biology Services
7.5.1. Biology Services Market, 2018 to 2030, (USD Million)
CHAPTER 8. DRUG DISCOVERY OUTSOURCING MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
8.4. Pharmaceutical & Biotechnology companies
8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 to 2030, (USD Million)
8.5. Academic Institutes
8.5.1. Academic Institutes Market, 2018 to 2030, (USD Million)
CHAPTER 9. DRUG DISCOVERY OUTSOURCING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. North America
9.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.2. U.S
9.4.2.1. Key Country Dynamics
9.4.2.2. Competitive Scenario
9.4.2.3. Regulatory Framework
9.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3. Canada
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4. Mexico
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Europe
9.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.2. UK
9.5.2.1. Key Country Dynamics
9.5.2.2. Competitive Scenario
9.5.2.3. Regulatory Framework
9.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3. Germany
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.4. Italy
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.5. France
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.6. Spain
9.5.6.1. Key Country Dynamics
9.5.6.2. Competitive Scenario
9.5.6.3. Regulatory Framework
9.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.7. Netherland
9.5.7.1. Key Country Dynamics
9.5.7.2. Competitive Scenario
9.5.7.3. Regulatory Framework
9.5.7.4. Netherland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.8. Belgium
9.5.8.1. Key Country Dynamics
9.5.8.2. Competitive Scenario
9.5.8.3. Regulatory Framework
9.5.8.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.9. Switzerland
9.5.9.1. Key Country Dynamics
9.5.9.2. Competitive Scenario
9.5.9.3. Regulatory Framework
9.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.10. Russia
9.5.10.1. Key Country Dynamics
9.5.10.2. Competitive Scenario
9.5.10.3. Regulatory Framework
9.5.10.4. Russia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.11. Sweden
9.5.11.1. Key Country Dynamics
9.5.11.2. Competitive Scenario
9.5.11.3. Regulatory Framework
9.5.11.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Asia Pacific
9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. China
9.6.2.1. Key Country Dynamics
9.6.2.2. Competitive Scenario
9.6.2.3. Regulatory Framework
9.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.3. Japan
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.4. Australia
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Framework
9.6.4.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.5. South Korea
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Regulatory Framework
9.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.6. India
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. Regulatory Framework
9.6.6.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.7. Thailand
9.6.7.1. Key Country Dynamics
9.6.7.2. Competitive Scenario
9.6.7.3. Regulatory Framework
9.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.8. Malaysia
9.6.8.1. Key Country Dynamics
9.6.8.2. Competitive Scenario
9.6.8.3. Regulatory Framework
9.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.9. Indonesia
9.6.9.1. Key Country Dynamics
9.6.9.2. Competitive Scenario
9.6.9.3. Regulatory Framework
9.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.10. Singapore
9.6.10.1. Key Country Dynamics
9.6.10.2. Competitive Scenario
9.6.10.3. Regulatory Framework
9.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.11. Philippines
9.6.11.1. Key Country Dynamics
9.6.11.2. Competitive Scenario
9.6.11.3. Regulatory Framework
9.6.11.4. Philippines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Latin America
9.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.2. Brazil
9.7.2.1. Key Country Dynamics
9.7.2.2. Competitive Scenario
9.7.2.3. Regulatory Framework
9.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Competitive Scenario
9.7.3.3. Regulatory Framework
9.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.4. Colombia
9.7.4.1. Key Country Dynamics
9.7.4.2. Competitive Scenario
9.7.4.3. Regulatory Framework
9.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.5. Chile
9.7.5.1. Key Country Dynamics
9.7.5.2. Competitive Scenario
9.7.5.3. Regulatory Framework
9.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8. MEA
9.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.2. South Africa
9.8.2.1. Key Country Dynamics
9.8.2.2. Competitive Scenario
9.8.2.3. Regulatory Framework
9.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.3. Saudi Arabia
9.8.3.1. Key Country Dynamics
9.8.3.2. Competitive Scenario
9.8.3.3. Regulatory Framework
9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.4. UAE
9.8.4.1. Key Country Dynamics
9.8.4.2. Competitive Scenario
9.8.4.3. Regulatory Framework
9.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.5. Kuwait
9.8.5.1. Key Country Dynamics
9.8.5.2. Competitive Scenario
9.8.5.3. Regulatory Framework
9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.6. Israel
9.8.6.1. Key Country Dynamics
9.8.6.2. Competitive Scenario
9.8.6.3. Regulatory Framework
9.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8.7. Egypt
9.8.7.1. Key Country Dynamics
9.8.7.2. Competitive Scenario
9.8.7.3. Regulatory Framework
9.8.7.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Market Participant Categorization
10.2. Company Market Share Analysis, 2024
10.3. Company Profiles
10.3.1. Albany Molecular Research Inc.
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. EVOTEC
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Laboratory Corporation of America Holdings
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. GenScript
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Pharmaceutical Product Development, LLC
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Charles River Laboratories
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. WuXi AppTec
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Merck & Co., Inc.
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Thermo Fisher Scientific Inc
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Dalton Pharma Services
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Oncodesign
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Jubilant Biosys
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. DiscoverX Corp.
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. QIAGEN
10.3.14.1. Company Overview
10.3.14.2. Financial Performance
10.3.14.3. Service Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Eurofins SE
10.3.15.1. Company Overview
10.3.15.2. Financial Performance
10.3.15.3. Service Benchmarking
10.3.15.4. Strategic Initiatives
10.3.16. Syngene International Limited
10.3.16.1. Company Overview
10.3.16.2. Financial Performance
10.3.16.3. Service Benchmarking
10.3.16.4. Strategic Initiatives
10.3.17. Dr. Reddy Laboratories Ltd.
10.3.17.1. Company Overview
10.3.17.2. Financial Performance
10.3.17.3. Service Benchmarking
10.3.17.4. Strategic Initiatives
10.3.18. Pharmaron Beijing Co., Ltd.
10.3.18.1. Company Overview
10.3.18.2. Financial Performance
10.3.18.3. Service Benchmarking
10.3.18.4. Strategic Initiatives
10.3.19. TCG Lifesciences Pvt Ltd.
10.3.19.1. Company Overview
10.3.19.2. Financial Performance
10.3.19.3. Service Benchmarking
10.3.19.4. Strategic Initiatives
10.3.20. Domainex Ltd.
10.3.20.1. Company Overview
10.3.20.2. Financial Performance
10.3.20.3. Service Benchmarking
10.3.20.4. Strategic Initiatives
